Evotec (EVO) said Thursday it expects 2025 revenue of 840 million euros to 880 million euros ($953.9 million to $999.3 million).
Four analysts polled by FactSet expect 851.4 million euros.
The AI-powered medical data collation firm said it expects a 2024 to 2028 compound annual growth rate of 8% to 12%.
Furthermore, the company said tariffs and potential US government funding cuts are expected to have a "limited impact" on its business. It is also planning to simplify its business model and reduce its asset portfolio by around 30%.
Additionally, Evotec plans to use automation and cost-lowering initiatives to produce around 50 million euros in gross savings by 2028 on top of a priority reset that is expected to deliver 40 million euros a year in savings.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。